Clinical Research Directory

Inclusion Criteria: 1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent. 2. the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology. 3. the stage IV according to the eighth edition of IASLC. 4. PS 0-2, the expected survival \> 3 months. 5. the age of 18-75 years. 6. no contraindication to treatment with immune checkpoint inhibitors. Exclusion Criteria: 1. the patients' compliance was poor, which violated the rules of the trial; 2. the patients with severe dysfunction of vital organs (heart, liver and kidney) ; 3. the patients with other malignant tumors; 4. the researchers considered that the patients should not participate in other conditions of the trial.